Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page
- Check4 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3.SummaryDifference0.2%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.2%

- Check33 days agoChange DetectedThe study page content appears unchanged; the screenshots show the same information with only minor formatting or metadata updates.SummaryDifference0.1%

- Check40 days agoChange DetectedThe change seems limited to the page's last-update timestamp; core study details, including eligibility criteria, endpoints, and locations, appear unchanged.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.5.0 is now shown, replacing the previous Revision: v3.4.3.SummaryDifference0.2%

- Check61 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.